China Chinese Patent Medicine Industry Report, 2012-2015

Synopsis

In recent years, China's Chinese patent medicine industry has been running in good condition, with the revenue increasing from RMB 142 billion in 2008 to RMB 360 billion in 2012 at a CAGR of 26.2%. Over the same period, the total profit maintained a CAGR of 26.6%, and the gross margin remained higher than the average level of the overall pharmaceutical industry.

In succession to the Opinions on Promoting the Development of Traditional Chinese Medicine Services and Trade, the Twelfth Five-Year Plan on the Development of Traditional Chinese Medicine and other favorable policies, the new National Essential Drugs List published in March 2013 increased the number of Chinese patent medicine from 102 in 2009 to 203, and the proportion in total quantity from 33% to 39%. As a result, China's Chinese patent medicine market demand is expected to grow rapidly in the next five years.

Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases, tumor diseases, respiratory system diseases, musculoskeletal diseases and digestive system diseases are top five categories of Chinese patent medicine for hospitals in China. The Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases occupies the largest market share, which remained at around 37% in 2006-2012. Outstanding enterprises producing Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases include Shandong Buchang Pharma (products include Guanxin Shutong Capsule and Naoxinshu Oral Solution), Tianjin Tasly Group (products include Compound Danshen Dripping Pills and Yangxue Qingnao Granule), Jinling Pharmaceutical (products include Mailuoning Injection and Mailuoning Oral Solution), Shijiazhuang Yiling Pharmaceutical (products include Tongxinluo Capsule and Shensong Yangxin Capsule), etc.

As China's Chinese patent medicine is gaining international recognition, coupled with the incentive from high profit (the operating margin is generally above 70%) and the development bottleneck of the chemical pharmaceutical industry, foreign enterprises and institutions such as Novartis, Merck, Johnson & Johnson, GSK have set foot in the Chinese patent medicine market through joint ventures and wholly-owned subsidiaries. For example, in early 2013, GSK announced to carry out drug development trying to use traditional Chinese medicinal ingredients in China.

China Chinese Patent Medicine Industry Report, 2012-2015 of ResearchInChina mainly includes the following contents:

  • Industrial policies, development status, regional market, import and export, development trend of China's Chinese patent medicine industry;
  • Development status of the raw material market of China's Chinese patent medicine industry as well as the development status and import & export of China's plant extracts;
  • China's Chinese patent medicine market segments, including Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases, tumor diseases, respiratory system diseases, etc.;
  • Operation, revenue structure, gross margin and profit forecast of China's 10 major Chinese patent medicine production enterprises.
Why http://www.chinamarketresearchreports.com

China Chinese Patent Medicine Industry Report, 2012-2015

Published By :Research In China
Price

Related reports :

  • China Independent Clinical Laboratory Industry Report, 2016-2020
    Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory market size has been growing radically in recent ...
  • China Yohimbine Industry Overview, 2017-2021
    Description As a kind of effective ingredient extracted from African yohimbe barks, Yohimbine is widely used abroad for male health products. At present, it is classified into yohimbine 8%, yohimbine 98% and yohimbine hydr...
  • Investigation Report on China Fat Emulsion Market, 2010-2019
    As an emulsion of soy bean oil, egg phospholipids and glycerin, fat emulsion injection provides essential fatty acids for people who are unable to get nutrition via an oral diet. The concept of fat emulsion dated back to the 1960s when hospi...
  • Investigation Report on China Ornidazole Market, 2010-2019
    As the third generation of nitroimidazole antibiotics, ornidazole is used to combat anaerobic bacterial and parasitic infections. It inhibits nucleic acid synthesis by disrupting the DNA of microbial cells. Compared with metronidazole and tinidazo...
  • Investigation Report on China Ioversol Market, 2010-2019
    As a non-ionic contrast medium, ioversol featuring low toxicity and few effects is mainly used to enhance the contrast of blood vessels in medical imaging. Containing iodine, ioversol works based on x-ray attenuation. Contrast medium is co...
  • Investigation Report on China Dydrogesterone Market, 2010-2019
    According to statistics, over 90% of Chinese adult women suffer from different kinds of gynecological conditions to different degrees. And for married urban women, the TOP5 gynecological disorders are genital tract infections (42.9%), menstrual di...
  • Investigation Report on China Propofol Market, 2010-2019
    As a short-acting amnestic agent, propofol features rapid recovery and few adverse effects. And it has been widely used in the maintenance of general anesthesia and sedation for critically ill patients. Generally used together with spinal anesthes...
  • Investigation Report on China Remifentanil Market, 2009-2018
    As a new generation of opiates, remifentanil (remifentanil hydrochloride) is an ideal intravenous anesthetic with short onset and good controllability. Remifentanil hydrochloride injection is a narcotic used for the maintenance of general anesthes...
  • Investigation Report on China Cinepazide Market, 2010-2019
    As a new generation of piperazine, cinepazide(cinepazide maleate) has been widely used in Europe and Japan. As calcium channel blocker, cinepazide can stop calcium from entering vascular smooth muscle cell and relax smooth muscle of cerebral vesse...
  • Investigation Report on China Deproteinized Calf Blood Extract Market, 2010-2019
    As a drug improving energy metabolism, deproteinized calf blood extract has received wide attention due to its efficacy in nervous system. Currently, it is mainly used to treat brain disease, nervous system disease, vascular disease, ulcer, burn, ...